Summary

for people ages 18-60 (full criteria)
healthy people welcome
at UC Davis
study started
estimated completion:
Raja Sivamani (ucdavis)

Description

Summary

Few studies have assessed the effects of Triphala and Rubia Cordifolia from a skin biophysical perspective. Here, we aim to understand how these herbs can modulate the skin's barrier properties and the gut microbiome.

Official Title

Pilot Study on the Effects of Oral Triphala and Rubia Cordifolia on the Gut Microbiome and Skin Biophysical Properties

Details

Herbal supplements such as Rubia cordifolia and Triphala [a mix of Emblica officinalis (Amalaki), Terminalia bellerica (Bibhitaki), and Terminalia chebula (Haritaki)] are commonly used for skin based treatments in India. However, the scientific evidence for their specific effects on the skin are scant. Rubia cordifolia is a root that is used in skin care for pigmentation and inflammation.1 Triphala is thought to have antioxidant properties and reduce inflammation in general. Herbs have been shown to modulate the gut microbiome, as previous studies have suggested that triphala may modify the gut microbiome.2

However, few studies have assessed the effects of these herbs from a skin biophysical perspective. Here, we aim to understand how these herbs can modulate the skin's barrier properties and the gut microbiome.

Keywords

Sebum Production Stool Microbiome Transepidermal Water Loss Facial Brrightness Erythema Wrinkles Facial Shine Facies Rubia Cordifolia Triphala

Eligibility

You can join if…

Open to people ages 18-60

for subjects:

  1. Age 18 to 60 years of age
  2. Subject must be able to read and comprehend study procedures and consent forms.

You CAN'T join if...

for subjects:

  1. Subject should be generally healthy and have no smoking history in the past one year.
  2. Subjects must have no history of diabetes, metabolic syndrome, known cardiovascular disease, malignancy, kidney disease, or chronic steroid use.
  3. Those who are unable to discontinue topical medications for two weeks.
  4. Those who are unable to discontinue systemic antibiotics or oral probiotics for one month prior starting the study.
  5. Those who are unable to discontinue their Triphala and Rubia Cordifolia regimen for one month prior to starting study.
  6. Subjects who are postmenopausal
  7. Those who are pregnant or breastfeeding
  8. Those that are prisoners or cognitively impaired
  9. Those who have a known allergy to Rubia cordifolia, Emblica officinalis, Terminalia bellerica, Terminalia chebula.

Location

  • University of California-Davis, Department of Dermatology accepting new patients
    Sacramento California 95816 United States

Lead Scientist

  • Raja Sivamani (ucdavis)
    Authored (or co-authored) 29 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Davis
ID
NCT03477825
Study Type
Interventional
Last Updated